Parkinson’s disease (PD) is a common neurodegenerative disorder affecting 1% of the population by the age of 65 years and 4-5% of the population by the age of 85 years.
Advances in Inhaled Technologies: Understanding the Therapeutic Challenge, Predicting Clinical Performance, and Designing the Optimal Inhaled Product
Inhaled medicines are designed mainly to provide safe and efficacious treatment of respiratory diseases, offering the potential advantages of targeted drug delivery such as reduced onset time and increased therapeutic ratio. However, as a flipside of targeted drug delivery, drug levels in the relevant effect compartment cannot be easily assessed.
A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial
Entolimod (CBLB502) is a Toll-like receptor 5 agonist in development as a single-dose countermeasure against total body irradiation.
Simulations Plus Announces Quarterly Cash Dividend
Cash dividend declared of $0.05 per share
Differential effects of methoxy group on the interaction of curcuminoids with two major ligand binding sites of human serum albumin
Curcuminoids are a group of compounds with a similar chemical backbone structure but containing different numbers of methoxy groups that have therapeutic potential due to...
Use of Preclinical Dog Studies and Absorption Modeling to Facilitate Late Stage Formulation Bridging for a BCS II Drug Candidate
Formulation changes are common during drug development either due to clinical or manufacturing considerations. These changes especially at later stages of drug development oftentimes raise questions...
ADMET Predictor™ 7.0 Release
Learn about all the new features in ADMET Predictor 7.0 and how they can help you.
Simulations Plus Sets Date for 1st Quarter 2014 Earnings Release and Conference Call
Conference Call to be on Thursday, January 9, at 4:15 PM ET
Simulations Plus Reports First-Quarter FY2014 Financial Results
Net sales increase 15.3% to first quarter record $2.641 million; Earnings up 16.7%
Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium
Pyrvinium pamoate (PP) is a potent noncompetitive inhibitor of the androgen receptor (AR). Using a novel method of target identification, we demonstrate that AR is a...
Evaluation and Optimisation of Current Milrinone Prescribing for the Treatment and Prevention of Low Cardiac Output Syndrome in Paediatric Patients After Open Heart Surgery Using a Physiology-Based Pharmacokinetic Drug-Disease Model
Milrinone is the drug of choice for the treatment and prevention of low cardiac output syndrome (LCOS) in paediatric patients after open heart surgery across Europe.
Population Pharmacokinetic Evaluation of Eslicarbazepine Acetate for Adjunctive Therapy in Refractory Partial Onset Seizures
Eslicarbazepine acetate (ESL), a once-daily antiepileptic drug (AED), is converted to eslicarbazepine, the primary active metabolite of ESL, after oral administration. The population pharmacokinetics (PK)…
Design, Synthesis, and in vitro Testing of Novel COX-2/COX-1 Inhibitors
To design,synthesize,and test new lead molecules that inhibit both COX-1 and COX-2 forms of the cyclooxygenase (COX) enzyme, with higher affinity for COX-2 than for COX-1.
Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury
The drug development industry faces multiple challenges in the realization of safe effective drugs.
Faruqi & Faruqi, LLP Launches An Investigation Against Simulations Plus, Inc. (SLP) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Simulations Plus, Inc.
Simulations Plus Reports Preliminary Revenues for First Fiscal Quarter FY2014
Revenues Increase 14.9% for New Record 1st Quarter
Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data
Fourteen drugs targeting protein kinases have been approved by the United States Food and Drug Administration (FDA) between the years 2000 and 2011.
3D QSAR and pharmacophore study of curcuminoids and curcumin analogs: Interaction with thioredoxin reductase
Curcumin is the yellow pigment of Curcuma longa that irreversibly inhibits the activity of thioredoxin reductase (TrxR) and forms adduct.
Simulations Plus Announces Change in Chief Financial Officer
John R. Kneisel, CPA, to Replace Momoko Beran, Retiring after More Than 20 Years of Service